Jul 31, 2019

Meet The Professors: Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma — Part 1: A special video supplement to a CME symposium held at the 2019 ASCO Annual Meeting featuring Dr Smith’s comments on the application of emerging research to patient care:

• Appropriate management of molecular subtypes of diffuse large B-cell lymphoma (DLBCL); challenges in improving outcomes with the addition of novel agents to front-line R-CHOP (0:00)
• Smart Start study: Final results with a rituximab/lenalidomide/ibrutinib lead-in before the combination with chemotherapy for patients with newly diagnosed DLBCL (3:25)
• Importance of the interval between diagnosis and treatment for newly diagnosed DLBCL and implications for bias in clinical trials (7:05)
• Risk of relapse with germinal center versus non-germinal center subtypes of DLBCL (8:19)
• Activity and tolerability of the recently FDA-approved anti-CD79b antibody-drug conjugate polatuzumab vedotin in combination with bendamustine/rituximab (BR) for relapsed/refractory (R/R) DLBCL (9:45)
• Activity of single-agent polatuzumab vedotin in patients with R/R DLBCL; integration of polatuzumab vedotin/BR into clinical practice (12:06)
• Therapeutic options and investigational approaches for R/R DLBCL (14:50)
• POLARIX: An ongoing Phase III trial comparing polatuzumab vedotin with R-CHP to R-CHOP for patients with previously untreated DLBCL (17:22)
• Variations in chimeric antigen receptor (CAR) T-cell constructs; activity and tolerability of different CAR T-cell therapy products for R/R DLBCL (19:37)
• Integration of CAR T-cell therapy into the treatment algorithm for R/R DLBCL (24:12)
• Neurologic toxicity and cytokine release syndrome associated with CAR T-cell therapy (27:01)
• Selection and sequencing of therapy for patients with R/R mantle cell lymphoma (MCL) (32:00)
• Drug activity and tolerability and patient quality of life with ibrutinib compared to acalabrutinib (34:42)
• Results of the Phase III ECOG-E1912 trial evaluating up-front ibrutinib/rituximab versus FCR (fludarabine/cyclophosphamide/rituximab) for younger patients with chronic lymphocytic leukemia (CLL) (38:05)
• Alliance A041202 trial: Efficacy and tolerability of ibrutinib alone or in combination with either rituximab or BR for older patients with untreated CLL (42:44)
• Response rates and duration of minimal residual disease (MRD) negativity with limited-duration nonchemotherapy combination regimens for previously untreated CLL (44:28)
• Risk assessment, prevention and management of venetoclax-associated tumor lysis syndrome (48:39)
• Activity and tolerability of acalabrutinib alone or in combination with obinutuzumab for CLL (54:44)
• Second- and third-line therapy options for patients with CLL (56:54)
• Perspective on the results of the Phase III RELEVANCE trial: Lenalidomide/rituximab (R²) versus rituximab/chemotherapy, each followed by maintenance rituximab, for patients with newly diagnosed follicular lymphoma (FL) (59:00)
• Available data with and current clinical role of R² for patients with R/R FL (1:0m49)
• Comparison of the activity and side-effect profiles of approved and investigational PI3 kinase inhibitors for R/R FL (1:04:02)
• Approach to choosing among brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD), standard AVD/bleomycin (ABVD) and response-adapted ABVD as first-line therapy for advanced classical Hodgkin lymphoma (1:06:24)
• Activity of brentuximab vedotin alone or in combination with nivolumab in patients with R/R Hodgkin lymphoma (1:09:48)

CME information and select publications